WuXi AppTec Webinar on Breakthrough Drugs Draws Strong Attendance

SHANGHAI, June 23, 2014 /PRNewswire/ -- More than 400 life science innovators recently tuned in to a global webinar hosted by WuXi AppTec to gain insights into the advancement of programs that ultimately have been designated by the U.S. Food and Drug Administration as breakthrough therapies. The breakthrough designation applies to specific drugs that treat serious medical conditions and show signs of substantial improvements over available therapies, and it enables their speedy development and commercialization.

A panel of renowned drug discovery veterans offered "the story behind the story" on the discovery and advancement of breakthrough drugs from Pharmasset, Merck, and Pfizer. These programs had started years before the breakthrough therapy designation was granted, overcoming enormous hurdles with many lessons learned.  The life science community's enthusiasm for the event highlighted the passion and commitment among companies large and small for developing new therapies that significantly advance the treatment of serious and life-threatening diseases.

"WuXi is delighted to host this event so that our collaborators can share their expertise and insights to help others discover and develop better medicines faster," said Dr. Ge Li, Chairman and CEO of WuXi AppTec.  "It's our honor to have played a role in some of the most exciting breakthrough therapy programs to date.  Together, we and our partners will continue to make important progress in delivering innovative new therapies to patients."

The on-demand webinar recording can be accessed online at: http://www.wuxiapptec.com/wxpress/wuxi-successfully-hosted-webinar-breakthrough-drugs/.

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
+1 (201) 585-2048
[email protected]

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
[email protected]

SOURCE WuXi PharmaTech

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED